The PumpKIN program builds on the NHLBI Pediatric Circulatory Support Program, which initiated funding for the development of novel circulatory support devices in 2004. The PumpKIN Program will support the realization of the most promising devices in order to gain FDA approval to begin clinical testing, which is anticipated by 2013.
The four PumpKIN contractors are Harvey S. Borovetz, PhD, University of Pittsburgh; Mark Gartner, PhD, Ension, Inc., Pittsburgh; Bartley P. Griffith, MD, University of Maryland School of Medicine; and Robert Jarvik, MD, Jarvik Heart, Inc., New York.
Dr. Griffith will present an update on his research during today's Mid-Day Symposium 4: Update on Pediatric MCS Therapy.
During Friday afternoon's poster sessions, there will also be an update from Ension, Inc.: "The Ension Pediatric Cardiopulmonary Assist System (pCAS): Progress and Current Status" (Abstract 651).
According to Dr. Baldwin, the contractors are on schedule and making good progress. He said the miniature pediatric devices are based on the latest technology for VAD and ECMO devices. Preliminary data to be presented at this meeting, and in other forums, suggest that these devices and technology have great promise to perform well in future pediatric patients, based on work ongoing at the PumpKIN study centers.
The International Society for Heart and Lung Transplantation (ISHLT) is a not-for-profit organization dedicated to the advancement of the science and treatment of end-stage heart and lung diseases. Established in 1981, the Society now includes more than 2,200 members from more
|SOURCE International Society for Heart & Lung Transplantation|
Copyright©2010 PR Newswire.
All rights reserved